This optimization improves inhibitory activity and WT-EGFR selectivity, while simultaneously increasing lipophilicity and blood-brain barrier permeability.141 It was approved in China in March 2020 and was demonstrated to be a well-tolerated third-generation EGFR TKI, which can be used as a first-line treatment option for EGFR mutated NSCLC, in a phase III trial (NCT03849768) in 2022. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.